Each year, pharmaceuticals, biotech organizations, academic institutions and law firms commit costly errors that happen due to poorly informed IP portfolio decisions. Relating to biological sequence search, here are nine serious mistakes we hate to see life science companies make.
Researchers often neglect to search antibody patents because it seems complex and due to the perception that there is nothing to be gained from it. Dangerous thinking!
Antibody searching, with the right tools, is in fact quite easy. And the gain is compelling: searching patents is the best way to learn about the competitive landscape because patents are published before scientific papers.
Everyone likes free biological sequence search.
A free IP sequence search usually involves the following steps: search the Genbank patent divisions on the NCBI BLAST web site, go through the alignments one by one, and lookup related patent information on the web.
Bad idea. Here are four reasons why.
Prior art searching in the life sciences is complicated. Tens of millions of patents and applications, dozens of file formats, and handfuls of search platforms force the professional patent searcher to jump through hoops to get answers.
BLAST is the most popular sequence comparison algorithm, but it was not built with intellectual property sequence search in mind. Here we discuss three problems with using BLAST alone for such sequence alignments.
China's recent approval of imports of certain genetically modified corn and soybean represents the beginning of a hopeful trend to gain access to their enormous market. According the the U.S. Commerce Department, the Chinese market for U.S. soybeans was $14 billion in 2013, and corn was a significant $3.5 billion.
Brazil has a rapidly growing economy and is highly invested in Biotechnology and the Life Sciences.
Understanding the Intellectual Property landscape of Brazil is key for a global life science company's success.
Our whitepaper talks more about biotech patents and an gives an example of how to blast search them.